Analysts’ Viewpoint on Global Market Scenario
Genital pain during or after sexual activity is known as dyspareunia or coitalgia. Painful sex can be experienced internally in the vagina, uterus, or pelvis as well as outwardly on the vulva. Sexual activity can be uncomfortable due to infections or underlying medical issues. Usually, the underlying source of discomfort is found and treated. Rise in number of women with painful coitus is expected to propel the global market during the forecast period. Dyspareunia treatment market trends include rise in prevalence of dyspareunia, which is augmenting the research and development in painful intercourse treatment or painful coitus treatment. Leading players in the market are investing and collaborating on novel drug options for dyspareunia treatment or coitalgia treatment.
A new non-estrogen topical medication called prasterone (Intrarosa) is available in the market and is licensed for the treatment of moderate-to-severe dyspareunia caused due to menopause. There have not been any direct comparison studies between prasterone and vaginal estrogen. In one trial, prasterone outperformed placebo and increased the female sexual function index scores after just 12 weeks of treatment. Prasterone is thought to function by locally converting androstenedione and testosterone to estrone and estradiol in the vagina. Most doctors consider this to be the second-line treatment for patients who do not wish to use estrogen due to its daily dosage and lack of proven superiority to estrogen. Additionally, less insurance coverage could be available for newer brand-name drugs such as Intrarosa and Imvexxy than for more seasoned estrogen supplements, restricting their availability.
The oral medication ospemifene is intended only for the treatment of moderate-to-severe dyspareunia brought on by GSM. Ospemifene, an estrogen agonist that was approved in 2013, functions as a selective estrogen receptor modulator in the vagina but does not seem to activate breast and endometrial cells. Typically, women who prefer not to use vaginal products or who are unable to do so are given this daily oral option. Ospemifene and vaginal estrogen have not been compared in head-to-head studies, unlike prasterone.
People prefer painless and instant recovery solutions over their injury or physical issues. Therefore, the demand for non-invasive treatment is increasing rapidly across the globe. The non-invasive treatment is one of the most sophisticated options for dyspareunia, as it is related to genital organs and people are not ready to take the risk. Hence, they prefer non-invasive treatments. This kind of treatment has minimal to no pain or discomfort, with no incisions, stitches, or any kind of scars. Long hospital stay is not required in this treatment unlike other surgeries. Non-invasive treatments carry very less risk of complications and are available at an affordable price. For instance, in May 2021, Pfizer and Myovant Sciences’ Myfembree (relugolix, estradiol, and norethindrone acetate) became the first once-daily U.S. Food and Drug Administration (FDA) approved treatment for heavy menstrual bleeding associated with uterine fibroids in premenopausal women, with treatment duration of up to 24 months. This milestone marked a critical step forward in a disease area that has previously had limited non-invasive treatment options and significant reliance on surgical procedures such as hysterectomies.
Dyspareunia is one of the most prevalent issues affecting postmenopausal women. According to the American College of Obstetricians and Gynecologists, more than 75% of women experience painful sex at some point (ACOG). Younger age, education below a college degree, urinary tract symptoms, poor to fair health, emotional issues or stress, and a decrease in household income of more than 20% are significant risk factors and predictors for dyspareunia. These can also result in sexual issues such as a lack of arousal and desire, which can be problematic in intimate relationships. Both emotional and physical health could be significantly affected by it. Dyspareunia can cause low self-esteem, negative body image, anxiety, and hypervigilance to pain. Recurrent or chronic genital or pelvic pain accompanied by sexual activity or sexual dysfunction that lasts for three months or more is known as male dyspareunia. The illness often causes humiliation and could be challenging for the patient and the doctor to discuss openly.
In terms of treatment type, the global market has been bifurcated into drug and drug-device combinations. The drug segment has been split into estrogens, miscellaneous vaginal agents, selective estrogen receptor modulators, and others. The drug segment accounted for the largest global dyspareunia treatment market share in 2021 due to recent drug approvals by the U.S. FDA. For instance, on August 5, 2022, the U.S. FDA approved Myovant Sciences and Pfizer's once-daily medication MYFEMBREE for the treatment of moderate to severe pain brought on by endometriosis. MYFEMBREE is currently available and will continue to be commercialized jointly by Myovant and Pfizer.
Based on the route of administration, the global dyspareunia treatment market has been segregated into oral and vaginal inserts. Oral is the most common route of drug administration. It is the most preferred route due to advantages such as non-invasiveness, patient compliance, and convenience of drug administration.
As per the dyspareunia treatment market analysis, North America accounted for a significant share of the global dyspareunia treatment in 2021. According to the World Health Organization (WHO), the prevalence of dyspareunia in the U.S. stands at around 10% to 20%, with the leading causes varying by age group. Painful sex or dyspareunia is reported among 7.5% of women in the U.K. The disease is linked to poorer sexual, physical, relational, and mental health. Asia Pacific is likely to be the fastest-growing region for dyspareunia treatment due to the increase in awareness about dyspareunia treatment among women in the region.
The report concludes with the company profiles section, which includes information about key players in the global dyspareunia treatment market. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the leading players in the market. Duchesnay, Inc., AMAG Pharmaceuticals, Inc., Amneal Pharmaceuticals, TherapeuticsMd, Inc., Myovant Sciences, Novo Nordisk, Inc., Pfizer, and Viatris Inc. are the prominent players in the global dyspareunia treatment business.
Each of these players has been profiled in the dyspareunia treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 689.0 Mn |
|
Market Forecast Value in 2031 |
More than US$ 1.02 Bn |
|
Growth Rate (CAGR) for 2022-2031 |
4.1% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2020 |
|
Quantitative Units |
US$ Mn/Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, the qualitative analysis includes market drivers, restraints, opportunities, key trends, and a parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global market for dyspareunia treatment was valued at US$ 689.0 Mn in 2021.
The global market is projected to reach more than US$ 1.02 Bn by 2031.
The global market grew at a CAGR of 9.3% from 2017 to 2021.
The global market for dyspareunia treatment is anticipated to grow at a CAGR of 4.1% from 2022 to 2031.
The drug segment held more than 63% share of the global market in 2021.
North America is expected to account for the major share of the global market during the forecast period.
Duchesnay, Inc., AMAG Pharmaceuticals, Inc., Amneal Pharmaceuticals, TherapeuticsMD, Inc., Myovant Sciences, Novo Nordisk, Inc., Pfizer, and Viatris, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Dyspareunia Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Treatment Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Dyspareunia Treatment Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate globally with key countries
5.3. Key Industry Events (mergers, acquisitions, partnerships, etc.)
5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Dyspareunia Treatment Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Treatment Type, 2017–2031
6.3.1. Drug
6.3.1.1. Estrogens, Miscellaneous Vaginal Agents
6.3.1.2. Selective Estrogen Receptor Modulators
6.3.1.3. Others
6.3.2. Drug-device Combination
6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Dyspareunia Treatment Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2031
7.3.1. Oral
7.3.2. Vaginal Inserts
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Dyspareunia Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Retail Pharmacies
8.3.2. E-commerce
8.3.3. Others
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Dyspareunia Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Dyspareunia Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment Type, 2017–2031
10.2.1. Drug
10.2.1.1. Estrogens, Miscellaneous Vaginal Agents
10.2.1.2. Selective Estrogen Receptor Modulators
10.2.1.3. Others
10.2.2. Drug-device Combination
10.3. Market Value Forecast, by Route of Administration, 2017–2031
10.3.1. Oral
10.3.2. Vaginal Inserts
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Retail Pharmacies
10.4.2. E-commerce
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Treatment Type
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Dyspareunia Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Type, 2017–2031
11.2.1. Drug
11.2.1.1. Estrogens, Miscellaneous Vaginal Agents
11.2.1.2. Selective Estrogen Receptor Modulators
11.2.1.3. Others
11.2.2. Drug-device Combination
11.3. Market Value Forecast, by Route of Administration, 2017–2031
11.3.1. Oral
11.3.2. Vaginal Inserts
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Retail Pharmacies
11.4.2. E-commerce
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Treatment Type
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Dyspareunia Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2017–2031
12.2.1. Drug
12.2.1.1. Estrogens, Miscellaneous Vaginal Agents
12.2.1.2. Selective Estrogen Receptor Modulators
12.2.1.3. Others
12.2.2. Drug-device Combination
12.3. Market Value Forecast, by Route of Administration, 2017–2031
12.3.1. Oral
12.3.2. Vaginal Inserts
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Retail Pharmacies
12.4.2. E-commerce
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Treatment Type
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Dyspareunia Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Type, 2017–2031
13.2.1. Drug
13.2.1.1. Estrogens, Miscellaneous Vaginal Agents
13.2.1.2. Selective Estrogen Receptor Modulators
13.2.1.3. Others
13.2.2. Drug-device Combination
13.3. Market Value Forecast, by Route of Administration, 2017–2031
13.3.1. Oral
13.3.2. Vaginal Inserts
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Retail Pharmacies
13.4.2. E-commerce
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Treatment Type
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Dyspareunia Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment Type, 2017–2031
14.2.1. Drug
14.2.1.1. Estrogens, Miscellaneous Vaginal Agents
14.2.1.2. Selective Estrogen Receptor Modulators
14.2.1.3. Others
14.2.2. Drug-device Combination
14.3. Market Value Forecast, by Route of Administration, 2017–2031
14.3.1. Oral
14.3.2. Vaginal Inserts
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Retail Pharmacies
14.4.2. E-commerce
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Treatment Type
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2021)
15.3. Company Profiles
15.3.1. Duchesnay, Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Company Financials
15.3.1.3. Growth Strategies
15.3.1.4. SWOT Analysis
15.3.2. AMAG Pharmaceuticals, Inc.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Company Financials
15.3.2.3. Growth Strategies
15.3.2.4. SWOT Analysis
15.3.3. Amneal Pharmaceuticals
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Company Financials
15.3.3.3. Growth Strategies
15.3.3.4. SWOT Analysis
15.3.4. TherapeuticsMD, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Company Financials
15.3.4.3. Growth Strategies
15.3.4.4. SWOT Analysis
15.3.5. Myovant Sciences
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Company Financials
15.3.5.3. Growth Strategies
15.3.5.4. SWOT Analysis
15.3.6. Novo Nordisk, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Company Financials
15.3.6.3. Growth Strategies
15.3.6.4. SWOT Analysis
15.3.7. Pfizer
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Company Financials
15.3.7.3. Growth Strategies
15.3.7.4. SWOT Analysis
15.3.8. Viatris, Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Company Financials
15.3.8.3. Growth Strategies
15.3.8.4. SWOT Analysis
List of Tables
Table 01: Global Dyspareunia Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 02: Global Dyspareunia Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 03: Global Dyspareunia Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Dyspareunia Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Dyspareunia Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 06: North America Dyspareunia Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 07: North America Dyspareunia Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 08: North America Dyspareunia Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 09: Europe Dyspareunia Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 10: Europe Dyspareunia Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 11: Europe Dyspareunia Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 12: Europe Dyspareunia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 13: Asia Pacific Dyspareunia Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 14: Asia Pacific Dyspareunia Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 15: Asia Pacific Dyspareunia Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 16: Asia Pacific Dyspareunia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Latin America Dyspareunia Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 18: Latin America Dyspareunia Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 19: Latin America Dyspareunia Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 20: Latin America Dyspareunia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 21: Middle East & Africa Dyspareunia Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 22: Middle East & Africa Dyspareunia Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 23: Middle East & Africa Dyspareunia Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 24: Middle East & Africa Dyspareunia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
List of Figures
Figure 01: Global Dyspareunia Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 02: Global Dyspareunia Market Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 03: Global Dyspareunia Market Attractiveness Index Analysis, by Treatment Type, 2022–2031
Figure 04: Global Dyspareunia Market Revenue (US$ Mn), by Drug Market, 2017–2031
Figure 05: Global Dyspareunia Market Revenue (US$ Mn), by Drug-device Combination Market, 2017–2031
Figure 06: Global Dyspareunia Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 07: Global Dyspareunia Market Attractiveness Index Analysis, by Route of Administration, 2022–2031
Figure 08: Global Dyspareunia Market Revenue (US$ Mn), by Oral, 2017–2031
Figure 09: Global Dyspareunia Market Revenue (US$ Mn), by Vaginal Inserts, 2017–2031
Figure 10: Global Dyspareunia Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 11: Global Dyspareunia Market Attractiveness Index Analysis, by Distribution Channel, 2022–2031
Figure 12: Global Dyspareunia Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031
Figure 13: Global Dyspareunia Market Revenue (US$ Mn), by E-commerce, 2017–2031
Figure 14: Global Dyspareunia Market Revenue (US$ Mn), by Others, 2017–2031
Figure 15: Global Dyspareunia Market Value Share Analysis, by Region, 2021 and 2031
Figure 16: Global Dyspareunia Market Attractiveness Analysis, by Region, 2021–2031
Figure 17: North America Dyspareunia Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 18: North America Dyspareunia Market Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 19: North America Dyspareunia Market Attractiveness Index Analysis, by Treatment Type, 2022–2031
Figure 20: North America Dyspareunia Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 21: North America Dyspareunia Market Attractiveness Index Analysis, by Route of Administration, 2022–2031
Figure 22: North America Dyspareunia Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 23: North America Dyspareunia Market Attractiveness Index Analysis, by Distribution Channel, 2022–2031
Figure 24: North America Dyspareunia Market Value Share Analysis, by Country, 2021 and 2031
Figure 25: North America Dyspareunia Market Attractiveness Analysis, by Country, 2022–2031
Figure 26: Europe Dyspareunia Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 27: Europe Dyspareunia Market Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 28: Europe Dyspareunia Market Attractiveness Index Analysis, by Treatment Type, 2022–2031
Figure 29: Europe Dyspareunia Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 30: Europe Dyspareunia Market Attractiveness Index Analysis, by Route of Administration, 2022–2031
Figure 31: Europe Dyspareunia Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 32: Europe Dyspareunia Market Attractiveness Index Analysis, by Distribution Channel, 2022–2031
Figure 33: Europe Dyspareunia Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 34: Europe Dyspareunia Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 35: Asia Pacific Dyspareunia Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 36: Asia Pacific Dyspareunia Market Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 37: Asia Pacific Dyspareunia Market Attractiveness Index Analysis, by Treatment Type, 2022–2031
Figure 38: Asia Pacific Dyspareunia Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 39: Asia Pacific Dyspareunia Market Attractiveness Index Analysis, by Route of Administration, 2022–2031
Figure 40: Asia Pacific Dyspareunia Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 41: Asia Pacific Dyspareunia Market Attractiveness Index Analysis, by Distribution Channel, 2022–2031
Figure 42: Asia Pacific Dyspareunia Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 43: Asia Pacific Dyspareunia Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 44: Latin America Dyspareunia Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 45: Latin America Dyspareunia Market Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 46: Latin America Dyspareunia Market Attractiveness Index Analysis, by Treatment Type, 2022–2031
Figure 47: Latin America Dyspareunia Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 48: Latin America Dyspareunia Market Attractiveness Index Analysis, by Route of Administration, 2022–2031
Figure 49: Latin America Dyspareunia Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 50: Latin America Dyspareunia Market Attractiveness Index Analysis, by Distribution Channel, 2022–2031
Figure 51: Latin America Dyspareunia Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 52: Latin America Dyspareunia Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 53: Middle East & Africa Dyspareunia Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 54: Middle East & Africa Dyspareunia Market Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 55: Middle East & Africa Dyspareunia Market Attractiveness Index Analysis, by Treatment Type, 2022–2031
Figure 56: Middle East & Africa Dyspareunia Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 57: Middle East & Africa Dyspareunia Market Attractiveness Index Analysis, by Route of Administration, 2022–2031
Figure 58: Middle East & Africa Dyspareunia Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 59: Middle East & Africa Dyspareunia Market Attractiveness Index Analysis, by Distribution Channel, 2022–2031
Figure 60: Middle East & Africa Dyspareunia Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 61: Middle East & Africa Dyspareunia Market Attractiveness Index Analysis, by Country/Sub-region, 2022–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Dyspareunia Treatment Market
